Recent filings detailing trading activity involving Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) common stock reveal notable patterns in insider transactions conducted by Millennium Management LLC and affiliated entities, including ICS Opportunities II LLC, Millennium Group Management LLC, and Israel A. Englander. The reporting period spanned from March 26 through March 30, 2026.
Analysis of these filings shows a substantial divergence between selling activity and buying volume. Specifically, the reported sales totaled an approximate value of $89,389. Conversely, the purchases made during the same time frame amounted to roughly $818,257. This net flow suggests significant accumulation by the reporting parties despite concurrent disposition of shares.
Detailed Breakdown of Trading Transactions
The reporting individuals disposed of a combined total of 3,250 shares of Sensei Biotherapeutics common stock through various transactions. These sales occurred across a price spectrum ranging from $25.8501 to $28.6882 per share.
- On March 26, two distinct groups of shares were sold. One group consisted of 583 shares, executed at a volume-weighted average price (VWAP) of $26.8797, with individual prices varying between $26.68 and $27.4650. A second sale involved 1,274 shares, which had a VWAP of $28.6882, with corresponding price ranges from $28.07 to $28.7651.
The following day, March 27, saw the disposal of 469 shares, recorded at a VWAP of $26.7652, with prices moving between $26.21 and $26.95. Additionally, 36 shares were sold at a VWAP of $27.3690, within a price range of $27.2322 to $27.68.
Further sales activity was noted on March 30. Here, 518 shares were liquidated at a VWAP of $25.8501, with prices fluctuating between $25.13 and $26.0734. Separately, 370 shares were sold at a price of $27.68 per share.
In contrast to the sales figures, the reporting entities acquired a total of 30,585 shares of Sensei Biotherapeutics common stock. The purchase prices spanned from $25.0784 to $29.9788 per share, accumulating in value to approximately $818,257.
The acquisition data is equally detailed: On March 26, notable purchases included 778 shares at a VWAP of $27.2267 (with prices from $26.66 to $27.62), and 1,327 shares recorded at a VWAP of $27.9467 (prices ranged from $27.70 to $28.4163). Further buying activity involved 2,601 shares at a VWAP of $28.8539 (prices ranging from $28.7072 to $29.51), and 1,025 shares acquired at a VWAP of $29.9788 (with prices spanning $29.79 to $30.105$).
The buying trend continued on March 27 with three separate transactions: 10,643 shares were bought at a VWAP of $26.2933 (prices from $25.9197 to $26.88); 4,384 shares were purchased at a VWAP of $27.2826 (prices from $26.9750 to $27.68); and 294 shares were bought at a VWAP of $28.1301 (prices ranging from $28.10 to $28.60). On March 30, the reporting persons completed four purchases: 2,992 shares at a VWAP of $25.0784 (prices from $24.495 to $25.1856); 4,995 shares at a VWAP of $25.9900 (prices from $25.50 to $26.48); 1,176 shares at a VWAP of $26.7000 (prices ranging from $26.50 to $26.90); and 370 shares were acquired at $27.68 per share.
Market Context and Valuation Metrics
The current trading price for Sensei Biotherapeutics stands at $20.43. This represents a decline of roughly 15% over the past week, although historical data shows the stock achieved an impressive 185% return over the preceding year. The company's shares are characterized by significant price volatility; its negative beta of -0.18 suggests that the stock frequently moves in opposition to broader market trends.
According to analysis provided by InvestingPro, Sensei Biotherapeutics appears undervalued at present levels, trading substantially below what is calculated as its Fair Value. This perceived valuation gap may account for the substantial net buying activity demonstrated by Millennium Management and related entities.
The transactions were executed by ICS Opportunities II LLC or other associated trading entities, with Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander maintaining voting control and investment discretion. The reporting persons explicitly disclaimed beneficial ownership of these shares, except to the degree of their pecuniary interest. Following the reported trades, the beneficial stake in Sensei Biotherapeutics common stock held by Millennium Management LLC was recorded at 131,370 shares on March 26, increasing incrementally to 142,360 shares by March 27, and further rising to 145,678 shares by March 30.
Corporate Milestones Driving the Pipeline
Beyond the trading data, several corporate developments underscore Sensei Biotherapeutics' strategic trajectory. The company has announced the initiation of a Phase 1b/2 clinical trial for its investigational therapy, PIKTOR. This specific drug combination, consisting of serabelisib and sapanisertib, is designed for patients with HR+/HER2- advanced breast cancer. The therapeutic approach targets the PI3K/AKT/mTOR pathway, making PIKTOR the company’s lead program following its acquisition of Faeth Therapeutics.
The strategic expansion was solidified by Sensei Biotherapeutics completing the acquisition of Faeth Therapeutics. This transaction secured $200 million in private financing, which is designated to advance the development of the company's cancer treatment pipeline. The incorporation of PIKTOR into Sensei’s development portfolio significantly strengthens its research capabilities.
Further bolstering the outlook, Leerink Partners initiated coverage on Sensei Biotherapeutics with an Outperform rating and established a price target of $50 for the stock. On an organizational level, the company granted stock options to 17 new employees, including a substantial allocation directed toward Anand Parikh, who has joined as the new Chief Operating Officer.
Financially, the firm maintains a market capitalization of $27.49 million. The balance sheet indicates that Sensei Biotherapeutics holds more cash than debt and possesses liquid assets that exceed its short-term obligations. Additionally, InvestingPro subscribers have access to comprehensive financial health metrics, which assign an overall